A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 364
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : mpMRI
Long Form : multiparametric MRI
No. Year Title Co-occurring Abbreviation
2020 18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 1. Improved Risk Stratification for MRI-Guided Transrectal Prostate Biopsies. AUC
2020 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy. csPCa, MRGB, PI-RADSv2.1
2020 68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future? ---
2020 A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection. AUC, CDRs, EM, MRI, PCa, PI-RADS, PSA, PSAD, US
2020 A deep dive into understanding tumor foci classification using multiparametric MRI based on convolutional neural network. ADC, CNN, DCE, DW, PDW, T2W, WELM
2020 A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50ng/ml. AUC, csPCa, MRI, ROC, SB, TB
2020 A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy. DILs, IMPT, NTCP, OAR, PBS, SIB, TCP
2020 Accuracy of abbreviated multiparametric MRI-derived protocols in predicting local staging of prostate cancer in men undergoing radical prostatectomy. aMRI, CI, cT2W, DCE, DWI, NPV, PCa, RP, sT2, tT2W
2020 Accuracy of multiparametric MRI in distinguishing the breast malignant lesions from benign lesions: a meta-analysis. DCE-MRI, DWI
10  2020 An Exploratory Study of Dose Escalation vs Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer. HIFU, IQR, PSA
11  2020 Apical periurethral transition zone lesions: MRI and histology findings. TZ
12  2020 Applications of Artificial Intelligence to Prostate Multiparametric MRI (mpMRI): Current and Emerging Trends. ML
13  2020 Assessment of DCE Utility for PCa Diagnosis Using PI-RADS v2.1: Effects on Diagnostic Accuracy and Reproducibility. AUC, DCE-MRI, DWI, PCa, PI-RADS, ROC, T2W
14  2020 Brain extraction on MRI scans in presence of diffuse glioma: Multi-institutional performance evaluation of deep learning methods and robust modality-agnostic training. DL, MRI
15  2020 Can Extraprostatic Extension Be Predicted by Tumor-Capsule Contact Length in Prostate Cancer? Relationship With International Society of Urological Pathology Grade Groups. EPE, ISUP, RP, TCL
16  2020 Can transrectal prostate ultrasound compete with multiparametric MRI in the detection of clinically significant prostate cancer? TRUS
17  2020 Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma. CaPTk, GBM, MRI, PFS, RP
18  2020 Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation. AUC, MRI-US, PCa, PI-RADS, PSA, PSAD, PV, XGBoost
19  2020 Comparison of 68Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4-20ng/ml before the initial biopsy. PCa, PSA, ROC
20  2020 Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1. AUC, bpMRI, CSPC, DCE-MRI, DWI, MRGB, PI-RADS v2.1, PSA, T2 WI
21  2020 Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. ---
22  2020 Comparison of machine learning algorithms to predict clinically significant prostate cancer of the peripheral zone with multiparametric MRI using clinical assessment categories and radiomic features. ADC, GrG, PC, PCa, UA, VOIs
23  2020 Comparison of Real-Time Virtual Sonography Navigation Versus BioJet Navigation on Magnetic Resonance Imaging-Guided Prostate Needle Biopsy: A Single Institutional Analysis. AEs, PCa, PZ, RVS, TB, TRUS, TZ
24  2020 Current Role of Multiparametric MRI and MRI Targeted Biopsies for Prostate Cancer Diagnosis in Germany: A Nationwide Survey. MRtb, PCa
25  2020 Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. GG, RP, TZ
26  2020 Development and External Validation of Multiparametric MRI-Derived Nomogram to Predict Risk of Pathologic Upgrade in Patients on Active Surveillance for Prostate Cancer. AS, PI-RADS
27  2020 Dosimetric evaluation of MRI-to-ultrasound automated image registration algorithms for prostate brachytherapy. DILs, STAPLE, TRUS
28  2020 Education of prostate MR imaging: commentary. ---
29  2020 Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer. ADC, AS, GG, GR
30  2020 Extraprostatic extension in prostate cancer: primer for radiologists. ADT, EPE, RP, RT
31  2020 Feasibility of integrating computer-aided diagnosis with structured reports of prostate multiparametric MRI. CAD
32  2020 Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis. PRISMA
33  2020 Histopathological features of prostate cancer conspicuity on multiparametric MRI: protocol for a systematic review and meta-analysis. PRISMA
34  2020 Hypogonadism and prostate cancer detection on multiparametric MRI and mpMRI-TRUS fusion biopsy. ---
35  2020 Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed? PSMA
36  2020 In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography? SUV
37  2020 Influence of the Location and Zone of Tumor in Prostate Cancer Detection and Localization on 3-T Multiparametric MRI Based on PI-RADS Version 2. PCa, PI-RADSv2, PZ, WMHP
38  2020 Limitations of abdominopelvic CT and multiparametric MR imaging for detection of lymph node metastases prior to radical prostatectomy. LN, MUSIC, NPV, PCa, PPV, RP
39  2020 Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. MRI, NAFL, NAFLD, NASH
40  2020 MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI. bpMRI, CI, csPCa, PSAD, ROC
41  2020 Multicenter Multireader Evaluation of an Artificial Intelligence-Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI. AI
42  2020 Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study. AS, FUS-GB, GS, NPV, PCa, PPV
43  2020 Multiparametric MRI and Whole Slide Image-Based Pretreatment Prediction of Pathological Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Multicenter Radiopathomic Study. LARC, RPS, TRG, WSI
44  2020 Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study. ADC, ADT, DCE, PCa, RCB, TROI/NROI
45  2020 Multiparametric MRI as a Non-Invasive Monitoring Tool for Children with Autoimmune Hepatitis. AIH
46  2020 Multiparametric MRI for prostate cancer diagnosis: current status and future directions. ---
47  2020 Multiparametric MRI-Based Radiomics for Prostate Cancer Screening With PSA in 4-10 ng/mL to Reduce Unnecessary Biopsies. AUC, PCa, PSA, PSAD, ROIs
48  2020 Multiparametric MRI-Based Radiomics Nomogram for Predicting Lymph Node Metastasis in Early-Stage Cervical Cancer. ADC, CE, CI, DWI, FS-T2 WI, LASSO, LNM, ROC-AUC, T1 WI
49  2020 Multiparametric MRI-Based Radiomics Nomogram for Predicting Lymphovascular Space Invasion in Endometrial Carcinoma. AUC, CI, DWI, EMC, LASSO, LVSI, ROC
50  2020 Multiparametric-MRI-Based Radiomics Model for Differentiating Primary Central Nervous System Lymphoma From Glioblastoma: Development and Cross-Vendor Validation. ADCs, AUC, CE-T1 WI, DWI, GBM, PCNSL
51  2020 New options for increasing the sensitivity, specificity and scope of synergistic contrast magnetic resonance imaging (scMRI) using Multiplied, Added, Subtracted and/or FiTted (MASTIR) pulse sequences. CSF, DIR, fMRI, GBCAs, IR, MASTIR, MASTIR, MR, MRI, PGSE, scMRI, scMRI, SIR, TE, TI, TPs
52  2020 Patient-Centered Outcomes From Multiparametric MRI and MRI-Guided Biopsy for Prostate Cancer: A Systematic Review. CENTRAL, PCOs
53  2020 Pattern of relapse and dosimetric analysis of a single dose 19Gy HDR-brachytherapy phase II trial. DIL
54  2020 Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy. GTVs, LEAD, MRI
55  2020 PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy. FFBF, NCCN, PI-RADS, RT
56  2020 PI-RADS Version 2.1: A Critical Review (AJR Special Series on Radiology Reporting and Data Systems). PI-RADS
57  2020 Pilot study comparing dominant intraprostatic lesion volume using Ga-68 prostate-specific membrane antigen PET-computed tomography and multiparametric MRI. DIL, PET-CT, PSMA, PSMA-TV, TL-PSMA
58  2020 Prognostic value of seminal vesicle invasion on preoperative multi-parametric magnetic resonance imaging in pathological stage T3b prostate cancer. BCR, PCa, RP, SVI
59  2020 Prospective Evaluation of 18F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI. GG, PSA, PSMA, SUV
60  2020 Prostate cancer local staging using biparametric MRI: assessment and comparison with multiparametric MRI. AUC ROC, bpMRI, DCE, DWI, EPE, MRI, PCa, T2W
61  2020 Prostate MR: pitfalls and benign lesions. ---
62  2020 Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy. AUC, BCR, CAPRA, MSKCC, RALP
63  2020 Prostatitis, the Great Mimicker of Prostate Cancer: Can We Differentiate Them Quantitatively With Multiparametric MRI? ADC, PCa, TTP, Ve, Vp
64  2020 Radiomics Based on Multiparametric Magnetic Resonance Imaging to Predict Extraprostatic Extension of Prostate Cancer. ADC, AUC, DCE, DWI, EPE, LASSO, PCa, T2WI
65  2020 Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer. MRSI, PET
66  2020 Role of multiparametric prostate MRI in the management of prostate cancer. TRUS
67  2020 Role of pre-biopsy multiparametric MRI in prostate cancer diagnosis: Evidence from the literature. PI-RADS
68  2020 Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-Risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is predictive of therapeutic response. ADT, MRD, RP
69  2020 Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer. eLND, hrPC, PBR, PC
70  2020 Spatial density and diversity of architectural histology in prostate cancer: influence on diffusion weighted magnetic resonance imaging. ADC, APC
71  2020 Staging of bladder cancer with multiparametric MRI. ---
72  2020 The performance of intravoxel-incoherent motion diffusion-weighted imaging derived hypoxia for the risk stratification of prostate cancer in peripheral zone. ADC, AUC, Ds, fp, GG, ISUP, IVIM, PCa, PZ, SVM
73  2020 The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer. CEUS, HIFU, PSA
74  2020 The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer. CRT, HNSCC, HSV, nonHSV
75  2020 The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer. BPH, DRE, PCa, PSA, PSAD, STURS-PB, TRUS
76  2020 Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor: time to change our practice? ---
77  2020 Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. EPIC, GI, GU, HDR, HRQoL, IB-VMAT, IPSS
78  2020 Use of Imaging to Optimise Prostate Cancer Tumour Volume Assessment for Focal Therapy Planning. ---
79  2020 Using decision curve analysis to benchmark performance of a magnetic resonance imaging-based deep learning model for prostate cancer risk assessment. CNN, csPCa, DCA, PSAD
80  2020 Utilization of imaging for staging in bladder cancer: is there a role for MRI or PET-computed tomography? MIBC, NMIBC, PET-CT
81  2020 Vesical Imaging-Reporting and Data System for Multiparametric MRI to Predict the Presence of Muscle Invasion for Bladder Cancer. AUC, CI, DCEI, DWI, MIBC, NPV, PPV, VI-RADS
82  2020 Voxel-based supervised machine learning of peripheral zone prostate cancer using noncontrast multiparametric MRI. AUROC, DTI, DWI, MRI, SVM, T2WI
83  2020 Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRI. IMRT, TCP
84  2020 What to expect from a non-suspicious prostate MRI? A review. NPV, PSAD
85  2020 What You Need to Know Before Reading Multiparametric MRI for Prostate Cancer. ---
86  2019 18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. PI-RADSv2, QALYs
87  2019 68Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU. GS, HIFU, PCa
88  2019 A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. AUC, ePLND, LNI, MRI, PCa, RP
89  2019 A review of optimal prostate biopsy: indications and techniques. DRE, MRI, PI-RADS2, PSA
90  2019 Abbreviated Biparametric Versus Standard Multiparametric MRI for Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. bpMRI, DOR, LR, PCa, SROC
91  2019 Accuracy of multiparametric magnetic resonance imaging for detecting extracapsular extension in prostate cancer: a systematic review and meta-analysis. ECE, PCa, T2WI
92  2019 Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging? AUC, MSKCC
93  2019 Assessment of PI-RADS v2 categories ≥ 3 for diagnosis of clinically significant prostate cancer. 3DTPMB, csPCa, TPMB
94  2019 Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study. IHC, T2W
95  2019 Barriers to obtaining prostate multi-parametric magnetic resonance imaging in African-American men on active surveillance for prostate cancer. ---
96  2019 Cartography-based quality control of prostate cancer care: a necessary ground to targeted focal therapy. ---
97  2019 Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference. GS, GU, PCa, WMHP
98  2019 Clinical evaluation of an MRI-to-ultrasound deformable image registration algorithm for prostate brachytherapy. DILs, HDR-BT, ROs, TRUS
99  2019 Clinical-radiomics nomograms for pre-operative differentiation of sacral chordoma and sacral giant cell tumor based on 3D computed tomography and multiparametric magnetic resonance imaging. ACC, AUC, CTE, DWI, SC, SGCT
100  2019 Clinically significant prostate cancer detection on MRI: A radiomic shape features study. csPCa, ROC, SAVR